159496-17-0

Basic information

• Product Name: 5-METHYL-[1',2',3',4',5'-13C5]URIDINE
• Synonyms: 5-METHYL-[1',2',3',4',5'-13C5]URIDINE;[1',2',3',4',5'-13C5]RIBOTHYMIDINE;5-Methyluridine-1',2',3',4',5'-13C5;DWRXFEITVBNRMK-SJXXUHQYSA-N
• CAS NO: 159496-17-0
• Molecular Formula: C₁₀H₁₄N₂O₆
• Molecular Weight: 263.27
• Product Categories: Carbohydrates & Derivatives, Heterocycles, Isotope Labeled Compounds, Nucleotides, Bases & Related Reagents
• Mol File: 159496-17-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 5-METHYL-[1',2',3',4',5'-13C5]URIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-[1',2',3',4',5'-13C5]URIDINE(159496-17-0)
• EPA Substance Registry System: 5-METHYL-[1',2',3',4',5'-13C5]URIDINE(159496-17-0)

Safety Data

• Hazardous Substances Data: 159496-17-0(Hazardous Substances Data)

Usage

Uses

Used in Biomedical Research:
5-METHYL-[1',2',3',4',5'-13C5]URIDINE is used as a research tool for studying the degradation of tRNA and its role in various cellular processes. The presence of 13C isotopes in its structure enables researchers to track and analyze the compound's interactions and metabolic pathways within cells.
Used in Colorectal Cancer Diagnosis:
5-METHYL-[1',2',3',4',5'-13C5]URIDINE is used as a biological marker for the early detection and diagnosis of colorectal cancer. Its presence in urine samples can indicate the presence of the disease, allowing for timely intervention and treatment.
Used in Pharmaceutical Development:
5-METHYL-[1',2',3',4',5'-13C5]URIDINE can be used in the development of targeted therapies for colorectal cancer. Its unique structure and properties make it a potential candidate for the design of novel drugs that can specifically target cancer cells and disrupt their growth and survival mechanisms.
Used in Clinical Trials:
5-METHYL-[1',2',3',4',5'-13C5]URIDINE can be employed in clinical trials to evaluate the efficacy of new treatments for colorectal cancer. Its presence in urine samples can serve as a biomarker to monitor the progress of the disease and the effectiveness of the treatment.
Used in Diagnostic Industry:
5-METHYL-[1',2',3',4',5'-13C5]URIDINE is used as a diagnostic marker in the development of new diagnostic tests for colorectal cancer. Its detection in urine samples can help healthcare professionals identify patients at risk and guide them towards appropriate treatment options.

Upstream product

• 65-71-4 thymin 
• 159496-09-0 [13C5]-1,2-di-O-acetyl-3,5-di-O-benzoyl-α,β-D-ribofuranose 
• 503173-76-0 [ribose-13C5]-1-(2-O-acetyl-3,5-di-O-benzoyl-β-D-ribofuranosyl)-5-methyluracil 
• 238096-51-0 <1,2,3,4,5-13C5>-1,2-O-isopropylidene-α-D-ribofuranose 
• 503173-75-9 ¹³C₅-1′, 2 ′-di-O-acetyl-3 ′ ,5 ′-di-O-benzoyl-β-D-ribofuranose 
• 126590-65-6 <1,2,3,4,5,6-13C6>-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 
• 159496-08-9 C₄⁽¹³⁾C₅H₁₆O₇S 
• 7288-28-0 2,4-bis(trimethylsiloxy)-5-methylpyrimidine 
• 503173-74-8 [ribose-13C5]-3,5-di-O-benzoyl-1,2-O-isopropylidene-α-D-ribofuranose 
• 503173-73-7 [glu-13C6]-1,2:5,6-di-O-isopropylidene-3-oxo-α-D-glucofuranose 

Downstream Products

• 156968-81-9 D-thymidine-1'2'3'4'5'-13C₅ 
• 666824-09-5 C₂₆⁽¹³⁾C₅H₃₂N₂O₇ 

Relevant articles and documents

NMR Spectroscopic Determination of the Solution Structure of a Branched Nucleic Acid from Residual Dipolar Couplings by Using Isotopically Labeled Nucleotides

Only a small set of magnetic-field-induced residual dipolar couplings is required to determine the global structure of branched nucleic acids. This is demonstrated for the example of the Holliday junction (shown schematically) after 13C labelin

Chemical synthesis of 13C labeled anti-HIV nucleosides as mass-internal standards

Synthesis of [13C5]-labeled anti-HIV nucleosides, e.g. d4T, ddI, ddA, is described. The methodology used has been optimized due to the very high cost of the starting compound. The key step of this approach was the stereoselective dehomologation of 1,2:5,6-di-O-isopropylidene-3-oxo-α-D-glucofuranose (2) with periodic acid and sodium borohydride, which gave optically pure ribose derivative as the exclusive product. Nucleoside derivatives 6a-c were obtained from ribosylation of 5 with persilylated nucleobases under Vorbru?ggen conditions. Deoxygenation of 9a-c under Corey-Winter conditions afforded the desired labeled nucleoside analogues 12a-c.

A multigram, stereoselective synthesis of D-[13C5]ribose from D-[13C6]glucose and its conversion into [13C5]nucleosides

The preparation of 13C-labeled ribonucleosides starting from D-[13D6]glucose in 45% overall yield is described. The key of this short synthetic way is the dehomologation of di-O-isopropylidene hexofuranose 2 with periodic acid and NaBH4 that afforded stereoselectively the labeled ribofuranose derivative 3 in high yield.

Chemical Synthesis of 13C-labelled Monomers for the Solid-Phase and Template Controlled Enzymatic Synthesis of DNA and RNA Oligomers

The preparation of 13C-labelled ribonucleosides starting from -glucose 1 and the corresponding nucleobases 5a-e or 6a-e (N6-benzoyl-adenine, N2-acetyl-guanine, N4-benzoyl-cytosine, uracil and thymine) in 47-66percent overall yield is described.Their subsequent transformation into 5'-O-dimethoxytrityl protected DNA-phosphoramidites and 5'-O-dimethoxytrityl-2'-O-trialkylsilyl protected RNA-phosphor-amidites for the solid phase synthesis of DNA- and RNA-oligomers and to 5'-O-ribo- and deoxyribo-nucleosidetriphosphates for template controlled enzymatic synthesis (polymerase- or reverse transcriptase reaction) has been carried out.